WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H461618
CAS#: 159978-02-6
Description: S 15261 is a new oral anti-hyperglycemic agent that increases insulin sensitivity in various insulin-resistant animal models.
Hodoodo Cat#: H461618
Name: S 15261
CAS#: 159978-02-6
Chemical Formula: C36H35F3N2O4
Exact Mass: 616.25
Molecular Weight: 616.680
Elemental Analysis: C, 70.12; H, 5.72; F, 9.24; N, 4.54; O, 10.38
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: S 15261; S-15261; S15261;
IUPAC/Chemical Name: 2-((2-methoxy-2-(3-(trifluoromethyl)phenyl)ethyl)amino)ethyl 4-(2-(2-(9H-fluoren-9-yl)acetamido)ethyl)benzoate
InChi Key: ASWYZRRXMGAWGN-UHFFFAOYSA-N
InChi Code: InChI=1S/C36H35F3N2O4/c1-44-33(26-7-6-8-27(21-26)36(37,38)39)23-40-19-20-45-35(43)25-15-13-24(14-16-25)17-18-41-34(42)22-32-30-11-4-2-9-28(30)29-10-3-5-12-31(29)32/h2-16,21,32-33,40H,17-20,22-23H2,1H3,(H,41,42)
SMILES Code: O=C(OCCNCC(OC)C1=CC=CC(C(F)(F)F)=C1)C2=CC=C(CCNC(CC3C4=C(C5=C3C=CC=C5)C=CC=C4)=O)C=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 616.68 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Duhault J, Berger S, Boulanger M, Della Zuana O, Lacour F, Wierzbicki M. General pharmacology of S 15261, a new concept for treatment of diabetes. Arzneimittelforschung. 1998 Jul;48(7):734-44. PubMed PMID: 9706374.
2: Caüzac M, Kohl C, Girard J, Pégorier JP. S-15261, a new anti-hyperglycemic agent, reduces hepatic glucose production through direct and insulin-sensitizing effects. Biochem Pharmacol. 2005 Aug 15;70(4):527-34. PubMed PMID: 15993851.
3: Marquié G, Duhault J, Espinal J, Petkov P, Jablenska R, Khallayoun S, Bennani N. S 15261, a novel agent for the treatment of insulin resistance. Studies on Psammomys obesus. Effect on pancreatic islets of insulin resistant animals. Cell Mol Biol (Noisy-le-grand). 1997 Mar;43(2):243-51. PubMed PMID: 9130608.
4: Pickavance LC, Wilding JP. Effects of S 15511, a therapeutic metabolite of the insulin-sensitizing agent S 15261, in the Zucker Diabetic Fatty rat. Diabetes Obes Metab. 2007 Jan;9(1):114-20. PubMed PMID: 17199726.
5: Marquié G, El Madani T, Solera ML, Duhault J, Espinal J, Khallayoun S, Bennani N. S15261, a novel agent for the treatment of insulin resistance. Studies on Psammomys obesus. Life Sci. 1997;61(18):1741-53. PubMed PMID: 9365221.
6: Duhault J, Lacour F, Boulanger M, Della-Zuana O, Ravel D, Wierzbicki M, Espinal J. S15261, a new compound for the treatment of the insulin resistance syndrome. Diabetologia. 1994 Oct;37(10):969-75. PubMed PMID: 7851691.
7: Espinal J, Lacour F, Berger S, Duhault J. S15261 antagonises amylin-induced impaired glucose tolerance. FEBS Lett. 1995 Jul 10;368(1):36-8. PubMed PMID: 7615084.
8: Russell JC, Ravel D, Pégorier JP, Delrat P, Jochemsen R, O'Brien SF, Kelly SE, Davidge ST, Brindley DN. Beneficial insulin-sensitizing and vascular effects of S15261 in the insulin-resistant JCR:LA-cp rat. J Pharmacol Exp Ther. 2000 Nov;295(2):753-60. PubMed PMID: 11046115.